In the United States and many places in Europe and Asia, Stem cells that are harvested and then transferred to another area of the patient’s body at the point of care is considered autologous use with minimal manipulation and is permitted under the practice of medicine. Once tissue is manipulated it is considered a bio-drug and requires regulatory approval as a drug.
Are there regulatory issues related to stem cell treatment?
